Advertisement

Non-Functioning Pituitary Tumours

  • R. N. Clayton
Chapter
Part of the Endocrine Updates book series (ENDO, volume 18)

Abstract

Sporadic pituitary tumours account for about 10% of all intracranial tumours (1). These are generally benign tumours although about 50% show histological evidence of invasion of the capsule or into surrounding structures (2). Between 0.1-0.2% of adenomas develop into frank carcinomas defined by metastatic spread, usually within the central nervous system but occasionally more distally (3,4). The peak incidence is between ages 30-60 years, being somewhat earlier in women (20-45 years) than in men (35-60 years) due to the greater frequency of prolactinomas in young women (5,6). Pituitary tumours are rare below the age of 20 years when the vast majority (86%) are prolactinomas, or corticotrophinomas (10%) (5).

Keywords

Pituitary Adenoma Pituitary Tumour Diabetes Insipidus Multiple Endocrine Neoplasia Type Pituitary Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gold E.B. 1981 Epidemiology ofpituitary adenomas. Epidemiology Reviews 3: 163–183.Google Scholar
  2. 2.
    Sautner D., Saeger W. 1991 Invasiveness of pituitary adenomas. Pathology Research Practice 187:632–63CrossRefGoogle Scholar
  3. 3.
    Doniach I. 1997 Pituitary carcinoma. In: Sheaves R., Jenkins P.J., Wass J.A.H., eds. Clinical Endocrine Oncology. Oxford: Blackwell 225–227Google Scholar
  4. 4.
    Pernicone P.J., Scheithauer B.W., Sebo T.J., Kovacs K.T., Horvath E., Young W.F., Lloyd R.V., Davis D.H., Guthrie B.H., Schoene W.C. 1997 Pituitary carcinoma: a clinicopathological study of 15 cases. Cancer 79:804–812PubMedCrossRefGoogle Scholar
  5. 5.
    Falgia G. 1993 Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinologica 129 (suppl) 1–5Google Scholar
  6. 6.
    Mindermann T., Wilson C.B. 1994 Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology 41:359–364PubMedCrossRefGoogle Scholar
  7. 7.
    Thakker R.V. 1998 Multiple Endocrine Neoplasia - Syndromes of the Twentieth Century. Journal Clinical Endocrinology Metabolism 83:2617–2620CrossRefGoogle Scholar
  8. 8.
    Agarwal S.K., Guru S.C., Heppner C., Erdos M.R., Collins R.M., Park S.Y., Saggar S., Chandrasekharappa S.C., Collins F.C., Speigel A.M., Marx S.J., Burns A.L. 1999 Menin interacts with the AP1 transcription factor Jun D and represses Jun D - activated transcription. Cell 96:143–152PubMedCrossRefGoogle Scholar
  9. 9.
    Corbetta S., Pizzocaro A., Peracchi M., Beck-Peccoz P., Faglia G., Spada A. 1997. Multiple endocrine neoplasia type 1 in patients with recognised pituitary tumours of different types. Clinical Endocrinology 47:507–512PubMedCrossRefGoogle Scholar
  10. 10.
    Farell W.E., Clayton R.N. 1999 Tumour suppressor genes in pituitary tumour formation. in Ballieres Clinical Endocrinology Metabolism 13 (3) Ed JRE DavisGoogle Scholar
  11. 11.
    Benlian P., Giraud S., Lahlou N., Roger M., Blin C., Holler C., Lenoir G., Sallandre J., Calender A., Turpin G. 1995 Familial acromegaly: a specific clinical entity - further evidence from the genetic study of a three generation family. European Journal of Endocrinology 133:45–456CrossRefGoogle Scholar
  12. 12.
    Teh B.T., Kytola S., Farnebo F., Bergman L., Wong F.K., Weber G. et al 1998 Mutation analysis of the MEN-1 gene in multiple endocrine neoplasia typel, familial acromegaly, and familial isolated hyperparathyroidism. Journal Clinical Endocrinology Metabolism 83:2621–2626CrossRefGoogle Scholar
  13. 13.
    Asa S.L., Horvath E., Kovacs K. 1993 Pituitary neoplasms: an overview of the clinical presentation, diagnosis, treatment, and pathology. In Endocrine Tumours, Blackwells Oxford Ed. Mazzaferri E.L., and Sarmann N.A. pp77–112Google Scholar
  14. 14.
    Leavens ME, Khouri K, Samaan NA, Schultz PN 1993. Non-adenomatons intrasellar and parasellar neoplasms in Endocrine Tumours Ed Mazzaferri EL & Samaan NA, Blackwells Oxford pp 179–196Google Scholar
  15. 15.
    Snyder P J. 1993. Gonadotroph adenomas. In Endocrine Tumours. Ed Mazzaferri EL & Samaan NA, Blackwells Oxford pp 152–166.Google Scholar
  16. 16.
    Snyder P J 1993 Clinically nonfunctioning pituitary adenomas. Endocrinology Metabolism Clinics North America. 22: 163–175.Google Scholar
  17. 17.
    Katznelson L, Alexander J M, Klibanski A, 1993. Clinically non-functioning pituitary adenomas. J.Clin.Endo.Metab. 76:1089–1094.CrossRefGoogle Scholar
  18. 18.
    Jameson J L, Klibanski A, Black PM other authors 1987. Glycoprotein hormone genes are expressed in clinically non-functioning pituitary adenomas. J.Clin.Invest. 80: 1472–1478PubMedCrossRefGoogle Scholar
  19. 19.
    Asa SL, Ezzat S. 1998. The cytogenesis and pathogenesis of pituitary adenomas. Endocrine Reviewers 19: 798–827.CrossRefGoogle Scholar
  20. 20.
    Faglia G, Ambrosi B 1997. Non-functioning pituitary adenomas. In clinical Endocrine Oncology Ed.Sheaves, Jenkins & Wass. Blackwells, Oxford pp 213–217.Google Scholar
  21. 21.
    Ambrosi B, Colombo P, Bochicchio D, Bassetti M, Masini B, Faglia G 1992. The Silent corticotrophinoma: is clinical diagnosis possible? J. Endocrinol Invest. 15:443–452.PubMedGoogle Scholar
  22. 22.
    Ikeda H, Yoshimoto T, Kovacs K, Horvath E 1995 Cushing ’s disease due to fmale gonadotroph adenoma of the pituitary. Clin. Endocrinol. 43:383–386Google Scholar
  23. 23.
    Clayton R.N, Pfeifer M, Atkinson AB, Belchetz P, Wass JAH, Kyrodinou E, Vanderpump M, Simpson D, Bicknell J, Farrell WE 2000. Different patterns of allelic loss (LOH) in recurrent human pituitary tumours provide evidence for multiclonal origins Clin. Cancer Research (in press).Google Scholar
  24. 24.
    Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A. 1990. Clinically non-functional pituitary tumours are monoclonal in origin. J.Clin.Invest. 86:336–340.PubMedCrossRefGoogle Scholar
  25. 25.
    Bates AS, Farrell WE, Bicknell EJ, McNicol AM Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN. 1997. Allelic delection in pituitary adenomas relects aggressive biological activity and has potential value as a prognostic marker. J.Clin.Endocrinol.Metab. 82:818–824.PubMedCrossRefGoogle Scholar
  26. 26.
    Molitch M.E. 1997 Pituitary incidentalomas. Endocrinology and Metabolism Clinics of North America 26: 725–740PubMedCrossRefGoogle Scholar
  27. 27.
    Burrow G.N., Wortzman G., Rewcastle N.B., Holgate R.C., Kovacs K. 1981 Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. New England Journal of Medicine 304: 156–158PubMedCrossRefGoogle Scholar
  28. 28.
    Chong B.W., Kucharczyk A.W., Singer W., George S. 1994 Pituitary MR: a comparative study of healthy volunteers and patients with microadenomas. American Journal of Neuroradiology 15:675–679PubMedGoogle Scholar
  29. 29.
    Hall W.A., Luciano M.G., Doppman J.L., Patronas N.J., Oldfield E.H. 1994 Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Annals of Internal Medicine 120: 817–820PubMedGoogle Scholar
  30. 30.
    Arafah BM, Prunty D, Ybarra J, Hlavia ML, Selman WA 2000. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactimaemia, and headaches in patients with pituitary adenomas. J.Clin.Endo Metab. 85:1789–1793.CrossRefGoogle Scholar
  31. 31.
    Stewart, PM, Maheshwaran S, Griffith J, Li J, Sheppard MC, Olliff J, Franklyn JA, 1993 Pituitary imaging is essential for women with moderate hyperprolactimaemia. Brit. Med. J. 306:507–508.PubMedCrossRefGoogle Scholar
  32. 32.
    Toogood AA, Beardwell CG, Shalet SM 1994. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin. Endo. 41:511–516.CrossRefGoogle Scholar
  33. 33.
    Ahmed S; Elsheikh M, Page RCL, Adams CBT, Wass JAH 1999. Outcome of trans-spheniodal surgery for acromegaly and its relationship to surgical experience. Clin. Endo, 50: 561–567.CrossRefGoogle Scholar
  34. 34.
    Turner HE, Adams BT, Wass JAH 1999 Trans-sphenoidal surgery for microprolactinoma an acceptable alternative to dopamine agonists. Eur. J Endocrinology. 140:43–47.CrossRefGoogle Scholar
  35. 35.
    Clayton, R.N. 1999. How many surgeons to operate on acromegalics patients? Clin. Endo, 50: 557–559.CrossRefGoogle Scholar
  36. 36.
    Arafah BM 1986. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J.Clin.Endocrinol.Metab. 62:1173–1179.PubMedCrossRefGoogle Scholar
  37. 37.
    Arafah BM, Kailani SH, Nekl KE, Gold RS, Selman WR 1994. Immediate recovery of pituitary function after trans-spheniodal resection of pituitary macroadenomas. J.Clin.Endocrinol.Metab 79:348–354.PubMedCrossRefGoogle Scholar
  38. 38.
    Ciric I, Mikheal M, Stafford T, Lawson L, Garces R, 1983. Trans-sphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. J.Neurosurg. 59: 395–340PubMedCrossRefGoogle Scholar
  39. 39.
    Ebersold MJ, Quast LM, Laws ER, Scheithauer B, Randall RV, 1986. Longterm results in transspheniodal removal of non-functioning pituitary adenomas. J.Neurosurg 64:713–719.PubMedCrossRefGoogle Scholar
  40. 40.
    Comtois R, Beauregard H, Somma M, Serri O, Jilwan-Aris N, Hardy J. 1991. The clinical and endocrine outcome to trans-sphenoidal microsurgery of non-secreting pituitary adenomas. Cancer 68: 860–866.PubMedCrossRefGoogle Scholar
  41. 41.
    Sassolas G, Trouillas J, Treluyer C, Perrin G 1993. Management of nonfunctioning pituitary adenomas Acta. Endocrinologica 129:21–26Google Scholar
  42. 42.
    Gittoes NJL, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, Stewart PM, 1998. Radiotherapy for nonfunctioning pituitary tumours. Clin. Endocrinol 48: 331–337.CrossRefGoogle Scholar
  43. 43.
    Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S, Littley D 1993. The long-term efficacy of conservative surgery and radiotherapy in control of pituitary adenomas. Clin. Endocrinol 38:571–578.Google Scholar
  44. 44.
    Bradley KM, Adams CBT, Potter CPS,Wheeler DW,Anslow PJ, Burke CW 1994. An audit of selected patients with non-functioning pituitary adenomas treated by transspheniodal surgery without irradiation. Clin.Endocrinol. 41: 655–659.CrossRefGoogle Scholar
  45. 45.
    Turner HE, Stratton IM, Byrne JV, Adams CBT, Wass JAH 1999. Audit of selected patients with non-functioning pituitary adenomas treated without irradiation - a follow-up study. Clin.Endocrinol. 51: 281–284.CrossRefGoogle Scholar
  46. 46.
    Turner HE & Wass JAH 1999. Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1: 147–151.PubMedCrossRefGoogle Scholar
  47. 47.
    Brada H, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, Rajan B, Traish D 1992. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenomas. Brit.Med.J. 304:1343–1346.PubMedCrossRefGoogle Scholar
  48. 48.
    Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. 1994 Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int. J. Rad. Oncol.Biol.Physics 30:557–565CrossRefGoogle Scholar
  49. 49.
    Miller JL, Spry NA, Lamb DS, Delahunt J. 1991 Blindness in patients after external beam irradiation for pituitary adenomas: two cases occurring after small daily fractionated doses. Clinical Oncology 3: 291–294CrossRefGoogle Scholar
  50. 50.
    Gratton-Smith P, Morris J 1992. Delayed radiation necrosis of the central nervous system in patients irradiated for pituitary tumours. J Neurol.Neurosurg. & Psychiatry 55: 949–955.CrossRefGoogle Scholar
  51. 51.
    Bulow B, Hagmar L, Orbaek P, Osterberg K, Erfurth EM, 2000.High incidence of psychiatric illness and increased prevalence of cognitive and psychosocial dysfunction in hypopituitary women without GH substitution. Proceedings of the American Endocrine Society. Toronto June 21–24 2000.Abs.1 21–72.Google Scholar
  52. 52.
    Jones A 1991. Radiation oncogenesis in relation to treatment of pituitary tumours. Clin.Endocrinol 35: 379–397.CrossRefGoogle Scholar
  53. 53.
    Bliss P, Kerr GR, Gregor A 1994. Incidence of second brain tumour after pituitary irradiation in Edinburgh 1962–1990. Clinical Oncology 6: 361–363.PubMedCrossRefGoogle Scholar
  54. 54.
    Peace KA, Orme SM, Padayatty SJ, Godfrey HPD, Belchetz PE 1998. Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoided surgery or medication. Clin.Endocrinol. 49: 391–396.CrossRefGoogle Scholar
  55. 55.
    Sheline G 1987. Pituitary tumours: radiation therapy in Clinical Endocrinology (eds Beardwell C & Robertson G) pp 106–139. Butterworths London.Google Scholar
  56. 56.
    Snyder P, Fowble B, Schatz N, Sarino P, Gennarelli T 1986. Hypopituitarism following radiation therapy of pituitary adenomas. Am. Journal of Medicine 81:457–462.CrossRefGoogle Scholar
  57. 57.
    Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. 1989. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Quart. Journal of Medicine 70: 145–160.Google Scholar
  58. 58.
    Rosen T, Bengtsson B-A. 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288PubMedCrossRefGoogle Scholar
  59. 59.
    Bates AS, van’t Hoff W, Jones PJ, Clayton RN. 1996 The effect of hypopituitarism on life expectancy. J. Clin.Endocrinol.Metab. 81:1169–1172PubMedCrossRefGoogle Scholar
  60. 60.
    Bates AS, Bullivant B, Sheppard MC, Stewart PM. 1999 Life expectancy following surgery for pituitary tumours. Clin. Endocrinol. 50:315–319Google Scholar
  61. 61.
    Tomlinson JW, Holden N, Hills R, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM. 2000 Premature mortality in 1014 patients with hypopituitarism. Journal of Endocrinology (suppl) 164:OC 41Google Scholar
  62. 62.
    Bulow B, Hagmar L, Mikoczy Z, Nordstrom C-H, Erfurth EM. 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 46:75–81Google Scholar
  63. 63.
    Bulow B, Hagmar L, Eskilsson J, Erfurth EM. 2000 Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J. Clin.Endocrinol.Metab. 85:574–584PubMedCrossRefGoogle Scholar
  64. 64.
    Beshyah SA, Johnston DG. 1999 Cardiovascular disease and risk factors in adults with hypopituitarism. Clin. Endocrinol. 50:1–15Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • R. N. Clayton
    • 1
  1. 1.Department of MedicineSchool of Postgraduate Medicine, Keele University, Stoke on TrentStaffordshire

Personalised recommendations